Skip to main content

Advertisement

SpringerLink
Log in

Impact of CAR-T cell therapy on treating viral infections: unlocking the door to recovery

  • Letter to the Editor
  • Published:
Human Cell Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Zhen A, Peterson CW, Carrillo MA, Reddy SS, Youn CS, Lam BB, et al. Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS. PLoS Pathog. 2017;13(12):e1006753.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Guedan S, Posey AD, Shaw C, Wing A, Da T, Patel PR, et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight. 2018;3(1):e96976.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, et al. Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J Virol. 2015;89(13):6685–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Proff J, Brey CU, Ensser A, Holter W, Lehner M. Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2-CH3 IgG spacer domains. J Transl Med. 2020;18(1):1–11.

    Google Scholar 

  6. Ramanathan A, Robb NC, Lutzko C. SARS-CoV-2 targets by T cells: A review of potential strategies for effective immunotherapy. Mol Ther Methods Clin Dev. 2021;23:428–45.

    Google Scholar 

  7. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5.

    Article  CAS  PubMed  Google Scholar 

  8. Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92–101.

    Article  CAS  PubMed  Google Scholar 

  9. Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2020;12(10): e11131.

    Google Scholar 

  10. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62.

    Article  CAS  PubMed  Google Scholar 

  11. Gust J, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2018;8(12):1404–19.

    Article  Google Scholar 

  12. Norelli M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739–48.

    Article  CAS  PubMed  Google Scholar 

  13. Lee DW, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Guedan S, et al. CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge. Front Immunol. 2019;9:2460.

    Article  Google Scholar 

  15. O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Brudno JN, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34(10):1112–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Teachey DT, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. 2013;121(11):1994–2004.

    Google Scholar 

  18. Howard SC, et al. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol. 2011;90(4):375–84.

    Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge their respective departments for the conduct of the study.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Microbiology, West Bengal State University, Kolkata, 700126, West Bengal, India

    Nobendu Mukerjee

  2. Department of Microbiology, Adamas University, Kolkata, 700126, West Bengal, India

    Swastika Maitra

  3. Department of Computational Biology and Biotechnology, Mahapurusha Srimanta Sankaradeva Viswavidyalaya, Guwahati, Assam, 781032, India

    Arabinda Ghosh

  4. Department of Rasa Shastra and Bhaishajya Kalpana, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, 221005, India

    Rohit Sharma

Authors
  1. Nobendu Mukerjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Swastika Maitra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arabinda Ghosh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rohit Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NM conceptualized the paper with support from SM. The first draft was curated by NM. The draft was reviewed and modified by RS with support from AG. All authors commented on subsequent revisions and provided references.

Corresponding authors

Correspondence to Arabinda Ghosh or Rohit Sharma.

Ethics declarations

Conflict of interest

The authors declare that there is no competing interests.

Ethics approval

Not applicable.

Provenance

Not commissioned; editorial review.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mukerjee, N., Maitra, S., Ghosh, A. et al. Impact of CAR-T cell therapy on treating viral infections: unlocking the door to recovery. Human Cell 36, 1839–1842 (2023). https://doi.org/10.1007/s13577-023-00942-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-023-00942-2

Keywords

Search

Navigation